Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
Alpha Tau (NASDAQ: DRTS) will present a corporate overview and update at the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alpha Tau (NASDAQ: DRTS) will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15am PT / 2:15pm ET in San Francisco.
CEO Uzi Sofer and CFO Raphi Levy will review recent achievements and the outlook for upcoming data milestones, and will host institutional 1-on-1 investor meetings. The presentation runs 11:15am–11:55am PT at Westin St. Francis. A webcast link will be posted on the company’s Events & Presentations page.
Details
News Market Reaction – DRTS
On Dec 18, the day this news came out, DRTS closed 4.16% above the previous close.
Data tracked by StockTitan Argus for the Dec 18 session.
Key Figures
- Conference date
- January 15, 2026
- J.P. Morgan 2026 Healthcare Conference presentation
- Presentation start time
- 11:15 AM PT
- Corporate overview session start
- Presentation end time
- 11:55 AM PT
- Corporate overview session end
Historical Context
-
First U.S. GBM patient treated with Alpha DaRT in pilot study.
-
Two pancreatic cancer Alpha DaRT abstracts accepted for ASCO GI 2026.
-
FDA IDE approval to start pilot study in recurrent prostate cancer.
-
December investor conference appearances and 1x1 meeting availability.
-
Q3 results with higher net loss and increased R&D spending.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
alpha-radiation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones -
JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
| Event: | J.P. Morgan 2026 Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 15, 2026 |
| Time: | 11:15AM PT – 11:55AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
Webcast: Link will be posted on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT ®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.